SOURCE: National Traders Association

August 28, 2012 09:00 ET

Where We Are Headed -- New Outlook on Eli Lilly and Company and Arena Pharmaceuticals, Inc.

JAKARTA, INDONESIA--(Marketwire - Aug 28, 2012) - Moments ago, NationalTradersAssociation.org introduced new coverage of Eli Lilly and Company (NYSE: LLY) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Full outlook, analysis and consensus opinion is available to readers via the links below.

www.NationalTradersAssociation.org/r/gov/3bb9_LLY
www.NationalTradersAssociation.org/r/gov/9516_ARNA

The consistent delivery of accurate analyses relies solely on two factors, namely: market awareness and industry insight. Recent market drivers include the recent surge of durable goods orders buoyed by aircraft related demand, Japan's reversing of earlier gains on news of downgraded economic assessments and news of policy direction expected from the Federal Reserve. When it comes to discovering the right edge at the right time, all these factors play into effect. For a deeper understanding of the mechanics behind these events and how it can affect your portfolio, please refer to our email newsletter delivered to your inbox.

National Traders Association is releasing new coverage on Eli Lilly and Company for its current position within the consumer durables sector. Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. A copy of this report featuring Eli Lilly and Company (NYSE: LLY) is available at: www.NationalTradersAssociation.org/r/gov/3bb9_LLY.

National Traders Association has released research on Arena Pharmaceuticals, Inc. for its changing role within the consumer durables sector. Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. The full research report on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) we welcome investors to visit: www.NationalTradersAssociation.org/r/gov/9516_ARNA.

Consider National Traders Association
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop -- long before they become the next top news on major financial networks.

Contact Information